Home
Solution
Impact
R&D
About
- Team and Board
News and Events
Contact

Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa

10 June, 2026

|In News, Press Release

|By Anna-Karin Lindqvist

Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa

Recent Posts

Xinnate får FDAs Fast Track-status för TCP-25 vid behandling av epidermolysis bullosa
Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa
The 3rd World Congress on Rare Skin Diseases: 01-03 July 2026
BIO International Convention: 22-25 June 2026
EADV Symposium 2026: 07-09 May 2026

Archives

June 2026
May 2026
February 2026
January 2026
December 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
January 2025
December 2024
September 2024
May 2024
March 2024
February 2024
March 2023
October 2022
September 2022
July 2022
March 2022
August 2021
October 2020
January 2020

Prev
Next

© 2026 Xinnate. All rights reserved